Clayton Duncan

Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK.

Otologic Pharmaceutics, Inc. develops treatment for acute hearing loss. Its product HPN1010 is an oral medication to treat acute hearing loss to reduce the development of permanent hearing disorders. The company was founded by Richard Kopke, Robert A. Floyd and Dave karlman and is headquartered in Oklahoma City, OK.

Otologic Pharmaceutics, Inc. develops treatment for acute hearing loss. Its product HPN1010 is an oral medication to treat acute hearing loss to reduce the development of permanent hearing disorders. The company was founded by Richard Kopke, Robert A. Floyd and Dave karlman and is headquartered in Oklahoma City, OK.

Otologic Pharmaceutics, Inc. develops treatment for acute hearing loss. Its product HPN1010 is an oral medication to treat acute hearing loss to reduce the development of permanent hearing disorders. The company was founded by Richard Kopke, Robert A. Floyd and Dave karlman and is headquartered in Oklahoma City, OK.

Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK.

Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK.